Tango Therapeutics Inc (TNGX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $4.32B
Last updated: Nov 17, 2026 at 4:15 PM ET
Tango Therapeutics Inc (TNGX) Statistics
Tango Therapeutics (TNGX) has a market cap of $4.32B and an enterprise value of $4.23B. Its share count is up 56.74% from a year earlier. Revenue fell 100.00% over the last 12 months from the 12 months before.
Total Valuation
Enterprise value is 2.01% below the market cap, as cash exceeds debt.
| Market Cap | $4.32B |
|---|---|
| Enterprise Value | $4.23B |
| Latest price (Nov 17, 2026) | $22.11 |
Key Dates
The next earnings report is expected on Mar 3, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 3, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 9, 2026 |
| Fiscal Year End | December |
Price Statistics
The stock is up 170.62% over 52 weeks and trades 6.11% below its 50-day average.
| Beta (1Y) | 1.68 |
|---|---|
| 52-Week Change | +170.62% |
| 1-Month Change | -6.03% |
| 3-Month Change | -12.26% |
| 6-Month Change | +8.92% |
| 5-Year Change | +76.95% |
| Total Return (1Y) | +170.62% |
| Total Return (3Y CAGR) | +42.74% |
| Total Return (5Y CAGR) | +13.26% |
| Return vs SPY (1Y) | +164.82% |
| Max Drawdown (1Y) | -36.57% |
| Max Drawdown (3Y) | -91.46% |
| Sharpe Ratio (1Y) | 1.08 |
| Correlation with SPY (1Y) | 0.24 |
| 50-Day Average | $23.55 |
| 200-Day Average | $23.01 |
| 52-Week Range | $7.83 to $34.39 |
| RSI (14 Days) | 45.2 |
| Average Volume (20 Days) | 4.15M |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 39.45x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 39.45x |
|---|---|
| Quick Ratio | 39.45x |
| Debt / Equity | 0.00x |
| Interest Coverage | 15.12x |
Returns and Efficiency
Return on equity is -21.22% over the last 12 months, against a 5-year average of -39.02%.
| Return on Equity (ROE) | -21.22% |
|---|---|
| Return on Assets (ROA) | -20.13% |
| ROE (5Y Average) | -39.02% |
| ROA (5Y Average) | -25.67% |
| ROIC (5Y Average) | -30.97% |
Scores
TNGX has a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Piotroski F-Score | 3 of 9 |
|---|---|
| Piotroski Strength | Average |
Income Statement
Revenue was $0 over the last 12 months.
| Revenue | $0 |
|---|---|
| Revenue Growth (YoY) | -100.00% |
| Gross Profit | -$479.00K |
| Operating Income | -$228.53M |
| Pretax Income | -$208.05M |
| Net Income | -$208.00M |
| Reported EPS (TTM) | -$1.37 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 95.16% of the $1.03B in total assets.
| Cash and Equivalents | $86.83M |
|---|---|
| Total Debt | $0 |
| Net Cash | $86.83M |
| Net Cash Per Share | $0.50 |
| Working Capital | $967.50M |
| Shareholder Equity | $980.17M |
| Book Value Per Share | $5.64 |
| Total Assets | $1.03B |
| Total Liabilities | $53.29M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $321.00K of capital spending, operating cash flow left -$150.41M of free cash flow.
| Operating Cash Flow | -$150.09M |
|---|---|
| Capital Expenditures | $321.00K |
| Free Cash Flow | -$150.41M |
| FCF Per Share | -$0.89 |
| Depreciation and Amortization | $1.79M |
Trailing 12 months through Sep 30, 2026.
Growth
Revenue grew 35.89% a year over 3 years.
| Revenue Growth (3Y CAGR) | +35.89% |
|---|---|
| Revenue Growth (5Y CAGR) | +52.13% |
| Book Value Per Share Growth (2Y CAGR) | +6.21% |
| Tangible Book Per Share Growth (2Y CAGR) | +6.21% |
Dividends and Yields
TNGX does not pay a dividend. Its free cash flow yield is -3.91%.
| FCF Yield | -3.91% |
|---|---|
| Buyback Yield | -25.33% |
| Shareholder Yield | -25.33% |
Analyst Forecast
Consensus estimates put revenue growth at -79.52% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | -79.52% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About TNGX
What is TNGX's market cap?
Tango Therapeutics has a market cap of $4.32B. Its enterprise value, which adds debt and subtracts cash, is $4.23B.
How many shares of TNGX are outstanding?
Tango Therapeutics has 173.93M shares outstanding. The count is up 56.74% from a year earlier.
Does TNGX pay a dividend?
No. Tango Therapeutics does not pay a dividend.
How much debt does TNGX have?
Tango Therapeutics has $0 of total debt and $86.83M of cash and equivalents, a net cash position of $86.83M.
TNGX pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors